Necrosis of dystrophic myofibers in Duchenne muscular dystrophy and mdx mice results from defects in the subsarcolemmal protein dystrophin that cause membrane fragility and tears in the sarcolemma, and these lead to the destruction of the myofibers. The present study specifically tests whether overexpression of mIGF-1 in mdx/mIGF-1 transgenic mice reduces myofiber breakdown during the acute onset phase of dystrophy (at 21 days). The extent of muscle damage and Evans blue dye (EBD) staining of myofibers was quantitated histologically for mdx/mIGF-1 and their mdx littermates from 15 to 30 days of age. Overexpression of mIGF-1 strikingly reduced the extent of myofiber damage (histology and EBD staining) by up to 97% in tibialis anterior and quadriceps muscles at 21-22 days after birth. In the mdx diaphragm, the onset of muscle breakdown was earlier (by 15 days after birth) but no significant protective effect of IGF-1 was apparent within the first month of age in mdx/IGF-1 mice. These novel observations show that increased mIGF-1 within mdx myofibers specifically reduces the breakdown of dystrophic muscle during the acute onset of muscle degeneration. This mechanism of action can account for the long-term reduced severity of the dystropathology in mdx mice that overexpress mIGF-1 and provides promising opportunities for therapeutic strategies.
INTRODUCTION
Defects in the membrane-associated protein dystrophin predispose the cell membrane of skeletal muscle fibers to break down, leading to necrosis of myofibers in the human condition Duchenne muscular dystrophy (DMD) and the mdx mouse model of DMD (reviewed in [1] ). Overexpression of insulin-like growth factor-1 (IGF-1) within skeletal muscles has been shown to reduce the severity of the dystrophy in mdx mice [2] and this was one of the first reports to demonstrate that modification of myofiber biology had beneficial therapeutic effects. Modulating the expression of other genes can help salvage the integrity of dystrophic myofibers [3] . For example, reduced dystropathology in mdx mice is seen where the growth factor myostatin is absent [4] or blocked by specific antibodies [5] and by overexpression of membrane-associated proteins such as utrophin [6] , integrin-a7 [7] , and ADAM-12 [8] . It has also recently been shown that pharmacological blockade of the inflammatory cytokine tumor necrosis factor-a (TNF-a) markedly reduces the onset of myofiber necrosis in dystrophic mdx muscle [9] .
Skeletal muscle-specific overexpression of the exon-1 Ea isoform of IGF-1 (called mIGF-1) in transgenic mdx/ mIGF-1 mice [2] reduces the pathology of dystrophic muscles; however, it is not clear whether this effect of mIGF-1 results from protection of dystrophic myofibers from necrosis, from improved regeneration of damaged muscle, or from a combination of these two. If muscle necrosis does not occur, then regeneration (that includes the inflammatory cell response, activation and proliferation of myoblasts, and myotube formation) is not required. The present study specifically tests the ability of mIGF-1 overexpression to protect dystrophic myofibers from muscle breakdown and necrosis, with a particular emphasis on the early acute phase of the pathology.
In some muscles of mdx mice, the first signs of a myopathy, characterized by the presence of eosinophilic hypercontracted myofibers, can be observed starting from day 1 after birth [10] ; however, such damage is not significant. The absence of dystrophin results in an abrupt onset of skeletal muscle necrosis in limb and paraspinal muscles around 21 days of age and this is followed by muscle regeneration [9, 11] . In the limb muscles of mdx mice the levels of MyoD and myogenin (as a measure of myoblast activation and regeneration) increase dramatically at around 21 days after birth and remain slightly elevated even at 13 months of age [12] , indicating ongoing regeneration. Radiographic studies similarly show that in the limb muscles of mdx mice myofiber breakdown peaks at 28 days and then decreases significantly to stabilize around 12 weeks of age to a relatively low level of damage [13] . The symptoms of dystropathology are cumulative and more pronounced in older (15 months) mdx mice [14] and slight changes in the rate of muscle breakdown are difficult to detect against this background of muscle pathology. In marked contrast, any change or delay in severity of the acute onset of damage at around 21 days of age, indicating a protection of muscle from breakdown, is readily detected. This is a clean system with no preexisting background damage that avoids complications with assessing bmoreQ or blessQ damage in older mdx mice. Muscle damage is assessed both histologically (evidence of myofiber necrosis and of myotubes formed approximately 3 days after muscle breakdown) and by injection of Evans blue dye (EBD) as a sensitive and early marker of myofiber damage/leakiness [15, 16] .
In the present study, quantitative histological analysis was performed on tissue sections from two limb muscles, tibialis anterior (TA) and quadriceps, and also from diaphragm muscles of young (15 to 30 days of age) and adult (12 weeks of age) mdx/mIGF-1 mice and nontransgenic control mdx littermates.
RESULTS
Myofiber Size in mdx and mdx/mIGF-1 Mice Since we hypothesized that the protective effect of mIGF-1 on dystrophic myofibers might be due to its hypertrophic action, we measured the myofiber cross-sectional area (CSA) in TA, quadriceps, and diaphragm muscles of day 19 and day 26 mdx and mdx/mIGF-1 mice and also in TA and diaphragm muscles of adult 12-week-old mice (Table 1) . The mean myofiber CSA was larger in 19-and 26-day-old mdx/mIGF-1 mice compared to mdx mice for all three muscles; however, this difference was statistically significant only for diaphragm muscle at 26 days of age. At 12 weeks of age the mean CSA of myofibers was also significantly larger in TA and diaphragm muscles of mdx/mIGF-1 mice compared to mdx mice by~30 and 17%, respectively (Table 1 ) and the distribution of all sizes of myofibers was shifted towards larger values (Figs. 1A and 1B).
Onset and Extent of Muscle Damage in Young (15-to 30-Day-Old) mdx and mdx/mIGF-1 Mice We assessed onset of muscle damage on transverse cryosections of the limb (TA and quadriceps) and diaphragm muscles of 15-to 26-day-old control mdx and mdx/mIGF-1 littermate mice by the presence of EBDpositive myofibers. We assessed myofiber necrosis and the presence of regenerated (centrally nucleated) myofibers on hematoxylin and eosin (H&E)-stained sections of the same muscles of 15-to 30-day-old mice.
Limb muscles. In TA muscles, we did not see myofibers containing EBD in 19-and 20-day-old mdx or mdx/ mIGF-1 mice and did not observe degenerating myofibers histologically (Table 2 , Figs. 2A and 2B ). We first saw myofibers with fragmented sarcoplasm at day 21 in most (7 of 9) of the TA muscles in mdx mice but in few (only 2 of 9) mdx/mIGF-1 TA muscles at this age (Table 2 , Figs. 2C and 2D). We also first detected EBDpositive myofibers at day 21 in all (9) TA muscles of mdx mice and in some (3 of 9) of the mdx/mIGF-1 mice (Table 2 , Figs. 2E and 2F). The incidence of damaged myofibers was consistently less in 21-to 30-day TA muscles of mdx/mIGF-1 mice compared to mdx mice (Table 2) . We saw evidence of muscle pathology documented by the presence of EBD-positive myofibers and/or necrotic and regenerated (centrally nucleated) myofibers for all 34 TA muscles of 21-to 30-day-old mdx mice (Table 2) . In marked contrast, 10 of the 35 
Data are means F standard deviation, n, number of individual muscles analyzed. * Statistical significance ( P b 0.05) for data compared at each time point.
mdx/mIGF-1 TA muscles analyzed at days [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] showed no signs of myofiber damage and appeared normal ( Table 2 ). The reduced muscle damage in mdx/ mIGF-1 compared with mdx muscles (Fig. 2) is further illustrated by quantitation of the area of affected muscle tissue at days 21-30 (Figs. 4A and 4B). We noted that the relatively large areas with EBD-positive myofibers seen at day 23 in mdx/mIGF-1 muscle (Fig.  4A) are not reflected by histological evidence of myofiber necrosis at this time (Fig. 4B) . In TA muscles of mdx and mdx/mIGF-1, we first saw a few myotubes (indicative of regeneration) at day 22, which corresponds with the classical description of the onset of myotube formation in mdx mice [11] . The onset, extent, and pattern of myofiber damage and myotube formation at these early ages in the littermate mIGF-1 null mdx mice were similar to those reported for conventional mdx mice [9] . In quadriceps muscles, the myopathy was evident slightly earlier, at day 19-20 after birth in mdx mice, with two of four quadriceps muscles containing EBDpositive myofibers and myofibers with disintegrated sarcoplasm (Table 2) . We saw some myofiber damage also in three of seven quadriceps muscles of mdx/mIGF-1 mice at days 19 and 20 ( Table 2) . From day 21 to 30 most of the quadriceps muscles of both strains displayed some evidence of myopathy ( (Figs. 3E-3H , 4B, and 4D). We also noted a lack of correlation between the areas of EBD-positive myofibers (Fig. 4C ) and extent of histological myofiber damage (Fig. 4D ) for quadriceps muscles of 21-day-old mdx mice.
The average areas occupied by EBD-positive myofibers and areas of composite damage were less in the limb muscles of day 21-30 mdx/mIGF-1 mice compared to their nontransgenic age-matched mdx littermates ( 4). This trend was present at all time points for both TA and quadriceps muscles and was statistically significant especially at days 21 and 22; however, large variations between mice were observed.
Diaphragm. Examination of transverse sections of diaphragms of 19-and 20-day-old mdx and mdx/mIGF-1 mice (Figs. 5F and 5G) showed the presence of centrally nucleated myofibers, indicating that these muscles had already undergone necrosis and regeneration at this early age. Therefore we sampled diaphragm muscles of younger (15-and 17-day-old) mice to determine the time of onset of muscle damage and to test the effect of IGF-1 overexpression.
We saw occasional isolated EBD-positive myofibers in some diaphragm muscles of 15-day-old mdx and mdx/mIGF-1 mice, although clustered EBD-positive myofibers were present in only one 15-day-old mdx diaphragm ( Table 2) . At day 17, all three diaphragms from mdx mice displayed occasional clusters of EBDpositive myofibers (Fig. 5B) . Such myopathology was less pronounced in 17-day-old mdx/mIGF-1 mice (Fig.  5C , Table 2 ), of which one of five diaphragms was completely intact, two had occasional isolated myofibers (similar to day 15), and two had a few clusters of EBD-positive myofibers.
The histological appearance of H&E-stained transverse sections of diaphragms was similar for all 15-and 17-day-old mice: while necrotic myofibers with fragmented sarcoplasm were not evident or were rare, numbers of inflammatory cells were slightly increased (Figs. 5D and 5E ). These observations again emphasize discrepancies between the presence of EBD-positive myofibers and histological evidence of myofiber necrosis, especially at early times (days [15] [16] [17] . Necrotic lesions and regenerated myofibers were detected in diaphragm muscles of mdx and mdx/mIGF-1 mice starting from day 19, and from day 23 all diaphragms contained centrally nucleated myotubes (Figs. 5F-5I). From the overall histological analysis, transverse samples of the diaphragm muscles of young mdx/mIGF-1 mice appeared thicker (wider) than for mdx mice (e.g., compare width in Fig. 5G with that in 5F, and 5I with 5H). However, as shown in Fig. 5A , the thickness (width) of the diaphragm muscle can easily vary between different regions of a single transverse section and it is difficult to make a precise comparison unless exactly the same region of the section is selected. For this reason, the average width of day 26 mdx and mdx/ mIGF-1 diaphragms was calculated based on measurements obtained from up to 20 different regions of the same muscle section. While the average width of mdx/ mIGF1 diaphragms appeared slightly greater (335 F 33 Am) then for mdx diaphragms (303 F 47 Am) at day 26, this difference was not statistically significant. It should also be emphasized that considerable variation occurred between individual mice. Furthermore, at this age, the average numbers of myofibers across different regions of the diaphragm muscles were similar in both transgenic and control mice.
Although myofiber damage was less pronounced in diaphragm muscles of mdx/mIGF-1 mice compared to mdx mice at early times (days 15 and 17) , quantitative analysis of the average areas occupied by EBD-positive myofibers ( Fig. 4E ) and areas of composite damage ( Quantitation of Muscle Damage in Adult (12-Week-Old) mdx and mdx/mIGF-1 Mice We quantitated areas of active muscle breakdown and regeneration (characterized by necrotic myofibers and/ or very small newly regenerated myotubes with the presence of inflammatory cells) in 12-week-old TA and diaphragm muscles of mdx (n = 4) and mdx/mIGF-1 (n = 6) mice. The extent of active damage was very 
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One muscle represents one mouse. Numbers of muscles that in a single cross section show any type of damage (i.e., presence of EBD-positive myofibers alone or in conjunction with necrosis and/or regeneration) are expressed as a percentage of the total number (n) of muscles analyzed at each age. Note. These data show only the incidence of tissue damage, they do not indicate the severity of the damage (i.e., extent of the muscle affected within the tissue section).
low compared with that seen in younger mice at the time of acute onset of the dystropathology; e.g., for the TA only~1-2% of the tissue was affected at 12 weeks compared to~20-40% at days 21-23 for mdx mice (see Fig. 4B ). We observed no significant differences between the strains at 12 weeks, although this might have been difficult to detect with such low levels of active muscle damage. This low level of active damage corresponds to little myofiber necrosis (~0.2% of the muscle affected) previously reported in 12-weekold mdx mice [9] . A cumulative index of pathology that measures muscle damage and regeneration over the life of the mouse is the presence of centrally nucleated myofibers. We quantitated the proportion of non-centrally nucleated myofibers (an indicator of the myofibers that have been spared from damage [11, 20] ) for TA muscles of mdx (n = 4) and mdx/mIGF-1 (n = 6) mice at 12 weeks, but the values of~26 and~29%, respectively, were not significantly different.
Type 2B Myofibers in Diaphragm Muscles of mdx and mdx/mIGF-1 Mice
Absence of type 2B myofibers has been previously reported in the diaphragm muscles of mdx mice and their background strain using histochemical staining [21] . Since dramatic hypertrophy of the adult mdx/ mIGF-1 diaphragm muscle was reported in response to mIGF-1 overexpression [2] , which is characterized by the highest expression level in type 2B myofibers [22] , we used antibodies to type 2B myosin to immunostain diaphragm muscles of 15-day-and 12-week-old mdx and mdx/mIGF-1 mice and also control 12-week-old nondystrophic MLC/mIGF-1 mice and their wild-type littermates (normal adult diaphragm 
DISCUSSION
This quantitative study demonstrates that muscle-specific overexpression of mIGF-1 has a protective effect on myofiber breakdown in the limb muscles (TA and quadriceps) of mdx/mIGF-1 mice during the acute onset of dystrophic muscle degeneration. These data support the hypothesis that a protective effect of mIGF-1 overexpression contributes substantially to the reduced pathology of the dystrophic muscle in adult mdx/mIGF-1 mice [2] .
Early Myofiber Protection in the Absence of Hypertrophy
The results of the present study indicate that at least in early stages of dystrophy, muscle hypertrophy is not a necessary prerequisite for the protection against degeneration afforded by mIGF-1 overexpression. In transgenic mdx/mIGF-1 mice [2] rat IGF-1 (isoform exon 1-Ea) is driven by the myosin light chain MLC-1/3 regulatory element that is expressed only in postmitotic muscle cells after differentiation (mainly myotubes and myofibers) [23] , with higher expression in fast-twitch (2B, 2X, and 2A) myofibers than in slow-twitch (type I) myofibers [22] . A very low expression level of MLC-1/3 promoter was reported in the diaphragm muscles of mouse embryos [24] . Characterization of 3-month-old mdx/mIGF-1 mice [2] showed about a twofold increase (from 8 to 14 ng/g) of total IGF-1 protein content in the limb muscles of these mice compared to nontransgenic mdx littermates with concomitant hypertrophy of limb muscles rich in type 2B myofibers, i.e., quadriceps, TA, and extensor digitorum longus (EDL), but not soleus. Such selective hypertrophy of limb muscles agrees with the selective expression of mIGF-1 transgene reported in nondystrophic MLC/mIGF-1 transgenic mice [17] . Significant hypertrophy of diaphragm muscle has also been reported in 3-month-old mdx/mIGF-1 mice and this increased with age up to 14 months [2] . The present study confirmed a significant hypertrophy in 12-week-old mdx muscles expressing mIGF-1 (Table 1) , in which the mean CSA of myofibers was increased by~30 and~17% for TA and diaphragm, respectively, with a greater incidence of very larger myofibers being present in mdx/mIGF-1 mice (Fig. 1) . While there was a trend toward larger myofibers for TA, quadriceps, and diaphragm muscles at earlier ages (19 and 26 days), this was not significant, except for the diaphragm muscle at 26 days of age (Table 1) . This increased myofiber size (hypertrophy) of day 26 mdx/ mIGF-1 diaphragm muscles was associated with a tendency for increased thickness, compared to control mdx muscles; however, this difference was not significant. Since the average number of myofibers across the diaphragm was also similar in young (26-day-old) transgenic and control mice, it seems likely that increased myofiber size in diaphragms of mdx/mIGF-1 mice at this stage might accordingly be associated with reduced interstitial-connective tissue, as was evident in diaphragm muscles of adult (14 month) mdx/mIGF-1 mice [2] . In summary, hypertrophy does not seem to be a key factor in the present study in which a protective effect was demonstrated in the limb muscles (TA and quadriceps) of young (15-to 30-day-old) mice, since at this early age no significant difference in myofiber size was observed between these muscles in mdx and mdx/mIGF-1 mice. Table 1 ).
express fast-type myosins initially, although it is not clear whether type 2B as well as type 2A myosins are coexpressed in such new muscle cells [25] . To test whether type 2B myosin is expressed by the myotubes or myofibers (formed in response to necrosis) in mature dystrophic diaphragms, immunostaining was carried out and compared with the pattern in normal (nondystrophic) age-matched controls and also with very young (15-day-old) dystrophic diaphragms sampled before the onset of myofiber necrosis. Type 2B myofibers were very rarely seen in the 15-day-old diaphragms, whereas they were conspicuous by 12 weeks of age in both dystrophic strains in which strong immunostaining was seen in small myotubes and large myofibers and these were often in clusters, indicating that they were regenerated myofibers resulting from focal necrosis (Figs. 6C and 6D ). The presence of type 2B myofibers would mean that mIGF-1 is concomitantly elevated in older mdx diaphragm with advanced pathology. This shift to type 2B myofibers after regeneration may persist for some time, since differentiation of regenerated myotubes into both slow and distinct fast muscle fiber types is markedly delayed in mdx muscles [25] , and slow tonic muscles in chickens do not return to their original fiber type pattern even by 3 months after regeneration [26] . Regenerated diaphragm muscle may be particularly resistant to conversion back into the original myofiber types and this transformation over time into type 2B myofibers may account for the greater size and many of the long-term benefits observed in dystrophic diaphragms of older mdx/mIGF-1 mice [2] . At 14 months of age the increased size of the EDL muscle was attributed to increased myofiber size, whereas diaphragm hypertrophy was due to increased myofiber number [2] . Variations in the pathophysio- logical response of different dystrophic muscles is demonstrated further by the present study, in which we describe (for the first time) the earlier onset of myofiber breakdown in the diaphragms of mdx mice (by 15 days after birth) compared to the limb muscles (at 19 days after birth) ( Table 2) . However, the extent of damage in diaphragm was lower than in limb muscles, at least up to 30 days (Fig. 4) , which is in agreement with other reports of the pattern of myofiber degeneration in diaphragm muscle [20, 27] . While there was a trend for reduced muscle damage in the diaphragm muscles of young mdx/mIGF-1 mice compared to mdx mice, this was not statistically significant. The differences between the response of diaphragm and limb muscles may in part relate to temporal and/or quantitative differences in the MLC promoter transcriptional activity in these various muscles [24] . Such differences between specific muscles must be considered when assessing the therapeutic value of mIGF-1 overexpression.
Age also plays a role in determining the extent of muscle sparing. By 12 weeks of age, no significant differences were detected in the extent of damage between mdx and mdx/mIGF-1 (TA and diaphragm) muscles. The extent of active muscle damage (characterized by areas of degenerating myofibers, newly regenerated very small myotubes, and presence of inflammatory cells) was very low in both TA and diaphragm muscles (compared with 3 weeks) and such decreased muscle damage after the initial acute phase of dystropathology has been widely reported for mdx mice [11] [12] [13] . Possibly due to this relatively very low level of active damage at 12 weeks (~1-3% of the muscle section affected), the present study found no differences in the extent of active muscle damage between TA and diaphragm muscle. However, other measurements, such as reduced serum creatine kinase levels and decreased EBD-positive myofibers, indicate reduced muscle damage in mdx/mIGF-1 compared with mdx mice at 3 months [2] .
Protection versus Regeneration
It has been suggested that the principal mechanism by which overexpression of mIGF-1 diminishes the dystropathology in adult mdx/mIGF-1 mice was increased muscle regeneration [2] . This hypothesis is supported by observations that overexpression of the mIGF-1 transgene improves muscle regeneration in 22-month-old nondystrophic MLC/mIGF-1 mice treated with cardiotoxin compared to age-matched nontransgenic (nondystrophic) control mice [17] and increases recruitment of bone marrow-derived Sca1-positive stem cells to the site of muscle injury induced by cardiotoxin in young adult MLC/mIGF-1 mice [28] . However, studies of regenerating whole muscle autografts do not show superior regeneration (with respect to revascularization, myoblast replication, or onset and number of myotubes formed) in MLC/mIGF-1 grafts compared to wild-type grafts [29] . While these differences may be attributed to the different models of regeneration used (cardiotoxin-induced damage compared to grafted avascular muscle), they show that mIGF-1 may not enhance regeneration in all situations.
Since the mIGF-1 construct is not expressed in quiescent, activated, or replicating myoblasts and levels of circulating IGF-1 are not elevated [17] , the effects of mIGF-1 on satellite cells (or bone marrow-derived stem cells) must be due to either a local paracrine mode of IGF-1 action or up-regulation of other factors within myofibers in response to overexpression of mIGF-1. The latter possibility is supported by up-regulation of endogenous IGF-1 isoforms including the Eb sequence in MLC/mIGF-1 mice [30] and also increased recruitment of Sca1-positive cells to the site of muscle injury (induced by cardiotoxin) in these transgenic mice [28] .
A beneficial effect of IGF-1 on dystrophic muscle through improved regeneration was also concluded from a study in 129 ReJ dy/dy mice (a model for a severe congenital muscular dystrophy caused by laminin deficiency), in which administration of human recombinant IGF-1 for 4 weeks increased the mass of EDL and soleus muscles and increased the specific force of EDL, but not soleus [31] , although no direct evidence was provided to support this conclusion. While the regenerative ability of dy/dy muscle is debated [32, 33] , muscle regeneration is generally considered to be excellent in mdx mice, even in the mdx diaphragm, which degenerates to a DMD-like pathology [27] , since recent studies conclude that the regenerative capacity is not exhausted even in this muscle [34] . If indeed regeneration is not normally a limiting factor in mdx muscles, then the beneficial effects of IGF-1 (or other factors) are more likely to be due to increased protection against breakdown than to an influence on regeneration, at least in the mdx dystrophic model.
How Does Elevated IGF-1 Reduce Necrosis of Dystrophic Muscle?
Previous studies (which used different ways to increase IGF-1 levels in dystrophic mice) proposed several explanations for a protective effect of IGF-1 on dystrophic muscle: a shift in myofiber type distribution to a more fatigue-resistant phenotype [21] , anabolic changes related to protein turnover, and hypertrophy or hyperplasia [2] . Systemic administration of recombinant human IGF-1 (1 mg/kg day) to adult (5 to 6 weeks of age) mdx mice for 8 weeks resulted in a fourfold increase in serum IGF-1 but not muscle IGF-1 and increased the specific force (bỹ 49%) and resistance to fatigue (by~30%) of mdx diaphragm muscle [21] . In this study no increase in myofiber size was observed in the diaphragm muscles following IGF-1 treatment; however, there was a shift of myofibers to the more oxidative (slow) phenotype, which is more resistant to fatigue (i.e., reduced proportion of 2X myofibers with a concomitant increase between type 1 and type 2A myofibers), with an increase in succinate dehydrogenase enzyme activity. Thus, a shift toward a more oxidative (slow) phenotype with increased resistance to fatigue might be beneficial for reducing contractile damage. Such a metabolic shift in myofiber types in EDL muscle of 3-month-old mdx/mIGF-1 mice was not apparent [2] ; instead, in older mice, overexpression of mIGF-1 within the myofibers prevented the normal loss of type 2B myofibers even in EDL muscles of 14-monthold mdx/mIGF-1 mice. The contrasts in physiological outcome between these studies are presumably due to the different IGF-1 isoforms and modes of delivery (systemic increase of circulating IGF-1 vs tissuerestricted production of a local IGF-1 isoform).
A recent study [35] proposed that calcineurin, which is a mediator of the IGF-1 signaling pathway in skeletal muscle cells [23] , plays an important role in the pathophysiology of mdx muscle. The inhibition of calcineurin by cyclosporin A administration to young (16-to 17-day-old) mdx mice for 16 days resulted in 300-400% more necrotic myofibers and a reduced number of centrally nucleated (regenerated) myofibers in the limb muscles [35] . While it was concluded that the effect of calcineurin inhibition was due to reduced or delayed regeneration, this could also reflect increased breakdown of dystrophic muscle due to the lack of IGF-1 signaling: it is difficult to distinguish between these two possibilities, since muscles were not examined during the acute time of myofiber necrosis, but only at a later single time point (around 33 days).
Inhibition of calpain-mediated pathways may be another mechanism whereby mIGF-1 overexpression can block early mdx muscle degeneration. In mdx mice, the increased total calpain concentration and an increase in calpain-1 autolysis has been shown at the peak of muscle pathology [36] and a mechanism for increasing calcium-dependent proteolysis in mdx muscle was proposed [37] , whereby the contractile activity dependent microlesions in the sarcolemma increases calcium entry into myofibers. This results in calpain activation locally under the sarcolemma that permanently alters the activity of calcium leak channels close to the wound site, which further increases calcium-dependent proteolysis [37] . Inhibition of calpain activity has been shown to be beneficial for protection of dystrophic myofibers from necrosis in young mdx mice [36, 38] .
A central role for mIGF-1 in potentially modulating the proteolysis involved in breakdown of dystrophic muscle is supported by two sets of observations. Inhibition of calpain pathways by the mIGF-1 transgene is illustrated by the prevention of calpainmediated breakdown of the CDK5 partner p35 (Musaro and Rosenthal, submitted for publication). The protective effect of locally synthesized mIGF-1 may also derive from inhibition of ubiquitin-mediated proteolytic breakdown, as mIGF-1 transgene overexpression prevented muscle atrophy in mice with left ventricular dysfunction by blocking ubiquitin-proteasome targeting of specific structural proteins (C. Schulze and N. Rosenthal, submitted for publication). Suppression of atrophy-related genes MAFbx and MuRF1, which encode ubiquitin ligases, by IGF-1 has been also shown in dexamethasone-treated C2C12 myotubes and short-term denervated atrophying muscles [39] .
The protective effect of muscle-specific mIGF-1 overexpression on mdx myofiber breakdown may also be related to overcoming the catabolic effects of TNF-a. In the complex in vivo situation, elevated TNF-a associated with inflammation increases catabolism within skeletal muscle and can interfere with IGF-1 signaling [9] and TNFa strongly inhibits IGF-1 gene and protein expression by muscle cells [40] . Therefore combined therapeutic strategies that block TNF-a activity [9] and elevate IGF-1 may prove more effective in the quest to reduce the breakdown of dystrophic myofibers.
It is not clear whether IGF-1 acts by protecting the myofiber against the initial membrane damage or whether it acts later to improve the efficiency of resealing of the sarcolemma after the focal lesion has occurred (Fig. 7) . There is little information on the speed required for myofiber resealing to prevent subsequent necrosis in vivo. Studies with electron microscopy [41] and penetration of horseradish peroxidase [42] show that at least 12 h (and up to 24 h) can elapse before myofibers reseal after experimental injury, yet the damage is restricted to the injured segment and does not spread throughout the myofibers even after this long interval. This raises interesting questions about the consequences of membrane lesions in skeletal muscle. Cell membrane resealing has been examined extensively in elegant studies in tissue culture in which vesicles accumulate to bpatchQ small lesions within about 60-90s for various cells [43] and also in myofibers injured by laser damage [44] . Exocytosis, Ca 2+ , and SNARE proteins appear to be involved and other proteins like dysferlin [44] and synaptotagmin VII [45] clearly play an important role in membrane resealing, with defects in these molecules leading to inflammatory myopathies. However, the timing and mechanism of sarcolemmal resealing in vivo remain obscure. While the precise mechanism for the protective effect of IGF-1 (e.g., reduced sarcolemmal damage or rapid repair of this initial damage, perhaps due to effects on proteolytic breakdown) requires further investigation, the present study demonstrates that increased levels of mIGF-1 within young mdx myofibers specifically reduce sarcolemmal damage and necrosis of dystrophic muscle. It remains to be determined to what extent this same mechanism operates in older mdx muscles in which the situation is further complicated by factors such as inflammation and fibrosis.
The ideal scenario for clinical therapeutic use of mIGF-1 in DMD is protection of myofibers from breakdown/necrosis to preserve the integrity of the muscle. The systemic effects of elevated IGF-1 can be diminished by a concomitant increase in the expression of IGF-binding proteins that inhibit IGF-1 action (IGFBP-2 and IGFBP-4) as has been shown in DMD human muscle [46] , focusing attention back onto strategies to increase local expression of IGF-1 within myofibers. Expression of endogenous IGF-1 is elevated in muscles of adult (8-to 10-week-old) mdx mice [47] as well as patients affected with DMD [46] , although information about the levels of various isoforms of IGF-1 at early and late stages of the dystropathology (even in mdx mice) is lacking. To harness the potential of IGF-1 as a strategy to reduce the pathology of DMD, the challenge is to find suitable interventions to elevate IGF-1 within myofibers for clinical application.
MATERIAL AND METHODS
Generation of mdx Â Â MLC/mIGF-1 mice. Transgenic MLC/mIGF-1 male mice (initially generated on FVB background) [17] were bred with dystrophic mdx female mice (mdx/mdx) (C57BL/10Sncn background) [18] . Male mice from the F1 generation (all carrying the mdx-affected maternal X chromosome (mdx/Y)) that screened positive for the MLC/ mIGF-1 transgene were bred with female mdx mice. All male and female mice in the F2 generation were dystrophin-negative as they carried the mdx-affected X chromosome(s) and these mdx mice were either positive for the MLC/mIGF-1 transgene or negative: the latter control mdx littermates are herein just referred to as mdx mice. The mice colonies were established at the Animal Resource Centre in Perth, Western Australia, and delivered under specific-pathogen-free conditions.
Experiments were performed on litters (male and female mice) at 15 to 30 days after birth and also on adult male 12-week-old mice. Animals were housed in standard animal cages and maintained on a 12-h light/dark regime with free access to standard chow and drinking water. Mice were screened postsampling for the presence of the MLC/mIGF-1 transgene by   FIG. 7 . Schematic representation of the events occurring following sarcolemmal damage in dystrophic myofibers. (A, B) Tears occur in the sarcolemma of dystrophic myofibers following physical exercise. (C) Such tears may be rapidly resealed within minutes by fusion of membrane vesicles to the edges of damaged sarcolemma, whereby (D) the myofiber returns to a relatively intact state. Alternatively, (E) if membrane vesicles fail to restore the damaged sarcolemma, necrosis of the underlying sarcoplasm takes place. Inflammatory cells rapidly invade the necrotic area and start to remove damaged tissue. (F) Necrosis is followed by regeneration, in which activated satellite cells proliferate, differentiate, and fuse to each other (to form myotubes) and to the damaged myofiber to replace the necrotic muscle segment. It is not clear whether the protective effect of mIGF-1 on dystrophic myofibers is due to decreased initial damage of the sarcolemma (B) or to increased resealing (C) or a combination of both mechanisms. Either situation could account for the decreased necrosis of dystrophic myofibers reported in the present study.
polymerase chain reaction using oligonucleotide primers specific for SV-40 forward, 5V -TGTTTATTGCAGCTTATAATGG-3V , and reverse, 5V -GGATC-CAGACATGATAAGATAC-3V (GeneWorks, Sydney, Australia) (fragment size 132 bp). Nontransgenic mdx littermates were used as controls for the transgenic mdx x MLC/mIGF-1 mice. All experiments were conducted in strict accordance with the guidelines of the University of Western Australia Animal Ethics Committee and the National Health and Medical Research Council, Canberra, Australia.
Injection of Evans blue dye. Injection of EBD was performed only in young 15-to 26-day-old mice (30-day-and 12-week-old mice were not injected). Mice were anesthetized with a gaseous mixture of 1.5% Rodia halothane (Merial), N 2 O, and O 2 ; weighed; and injected with 1% EBD (Sigma, St. Louis, MO, USA) (w/v) in phosphate-buffered saline (pH 7.5) by intraperitoneal injection into the right peritoneal cavity at a dose of 100 Al per 10 g of body weight [16] . Prior to injection, EBD solution was sterilized by passage through a Millex-GP 0.22-Am filter (Millipore, Bedford, MA, USA) and stored at 48C.
Tissue sampling and processing. Mice were anesthetized (as described above) and euthanized by cervical dislocation. Sampling of mice injected with EBD was performed 24 h after injection. TA and quadriceps muscles were excised, cut transversely in the central area, mounted onto tragacanth gum, and frozen in isopentane quenched in liquid nitrogen. The entire diaphragm was removed together with the ribcage, blotted, stretched onto a filter paper, separated from the ribs, cut transversely into two pieces in the central area, and mounted onto tragacanth gum using a microscope to ensure proper orientation of the tissue (Fig. 5A ). Transverse frozen sections (8 Am) were analyzed for bright red fluorescence of EBD using a fluorescence microscope Leica PM RBE with excitation filter BP 515-560 and emission LP 590 (green wavelength filter set) [16] . One section from each specimen was also stained with H&E for histological analysis.
Tissue analysis. The extent of muscle damage and regeneration was assessed using transverse sections of the limb muscles (TA and quadriceps) and diaphragm. In 15-to 26-day-old mice, EBD was used to identify leaky myofibers with permeable sarcolemma [16] and the area of the entire muscle section occupied by EBD-positive myofibers was measured. Areas of (i) muscle degeneration characterized by the loss of sarcoplasmic structure with necrosis of myofibers and infiltration of inflammatory cells and (ii) regeneration characterized by the presence of centrally nucleated myotubes and/or myofibers were measured on H&E-stained sections. Total areas of (i) degenerated and (ii) regenerated muscle were summed up to obtain a cumulative area of muscle damage, which herein is referred to as composite muscle damage.
Morphometric analysis was performed on digital images of the tissues. Slides were placed on a Leica PM RBE microscope connected to a personal computer and a video camera (Hitachi HV-C20M for brightfield images and Nicon TE-300 for EBD fluorescence images). Nonoverlapping images of the entire cross-sectional area of the muscles were taken using ImagePro Plus 4.0 (Microsoft) software and tiled to reconstitute the whole image of the muscle. Areas of muscle damage and regeneration were measured using ImagePro Plus 4 software and expressed as the proportion of the whole muscle cross-sectional area.
The CSA of myofibers was measured by tracing individual myofibers using ImagePro Plus 4.0 (Microsoft) software in the muscles of 19-day-, 26-day-, and 12-week-old mdx and mdx/mIGF-1 mice. In day 19 and day 26 mice, measurements were based on 50 non-centrally nucleated myofibers per muscle from two nonoverlapping fields. In 12-week-old mice, measurements are based on 200-300 myofibers per muscle from five nonoverlapping fields.
Immunocytochemistry with antibodies for type 2B myosin. Mouse antitype 2B myosin antibody (clone 10F5) [19] (undiluted supernatant) in combination with Alexa Fluor 488 goat anti-mouse IgM (No. A21042, Molecular Probes, Sydney, Australia) was used to visualize type 2B myofibers on diaphragm muscle sections. Binding of endogenous mouse immunoglobulins was blocked using the Vector M.O.M. immunodetection kit (No. BML-2202, Vector Laboratories, Sydney, Australia).
Statistical analysis. Statistical analysis was performed using the t test and differences were considered significant when P b 0.05.
